Lacerta Bio was pleased to take part in a terrific overview of technologies for oral delivery of peptides and proteins: The oral delivery of biopharmaceuticals is highly desirable because it…
This week, our good "acquaintances" from EBD Group launched partnering360. What is it? According to EBD: partnering360™ is an online network of professionals in the life science industry, emerging from…
Lacerta Bio spent the week at the AAPS ( American Association of Pharmaceutical Scientists ) annual conference . Over 8,000 pharmaceutical scientists, service providers, and others came to AAPS in…
Call us late to the party, but in August of this year, KPMG published Future Pharma: Five Strategies to Accelerate the Transformation of Pharmaceutical Industry... The entire report is available…
In our view, there are two basic types of biotech business development-related due diligence. The first is external , where the team gathers and analyzes data about a target company…
In a few weeks, Lacerta Bio will return to DC to participate in the annual convention and celebrate the 25th anniversary of the American Association of Pharmaceutical Scientists (AAPS). AAPS…
Earlier this month, Keith Powell posed an interesting question: The economies of California and the UK are similar, as are the university networks. Why then, does California boast the most…
What do companies such as Twitter, Facebook, and Google have in common with Pfizer, Amgen, BioMarin, Alkermes, and Jazz Pharmaceuticals? Dublin. All of them have set up international operations in Dublin, in…
Some members of the media are ebullient with the news that Merck is "getting into venture capital." However, as In Vivo is reporting, Merck is undertaking two initiatives that are…
Lacerta Bio was fortunate to attend this year's BioPharm America conference in Boston. Here are a few of our comments and observations: Are Specialty Markets the Future? - Moderated by…